Webinars and Sponsored Roundtables — Register Now

Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.

Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy,  CEO of mTuitive.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice

Webinar presenters Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Subspecialties

Interactive Product Guides

Marketplace Directory

Performance analytics, 10/16

October 2016—Visiun showcased its predictive analytics and population health reporting, which was added to its flagship product, Performance Insight. The predictive analytics, added to the comprehensive test-use module, are designed to enable laboratories to identify high-risk patients with both elevated patient risk and care gaps.

Sekisui Diagnostics, Qualigen partnership, 10/16

October 2016—Sekisui Diagnostics and Qualigen announced a strategic partnership encompassing current business and future collaboration opportunities. Sekisui Diagnostics has assumed commercial activities and distribution management for the FastPack IP System and associated products in U.S. and international markets.

R-Biopharm, GSD strategic alliance, 10/16

October 2016—Gold Standard Diagnostics announced a strategic alliance with R-Biopharm AG (Darmstadt, Germany) to collaborate on multiple technology and marketing initiatives that will leverage the companies’ respective strengths in expanding product offerings and geographic sales coverage.

Hydrocodone, Brahms PCT assays, 10/16

October 2016—Thermo Fisher Scientific exhibited its expanded offering of new assays, instruments, and software designed specifically for customers working in research and clinical settings. The Thermo Scientific DRI Hydrocodone assay detects hydrocodone in specimen samples and is FDA 510(k) cleared.

Pipettes, 10/16

October 2016—BrandTech Scientific featured its line of Brand liquid handling products, including the Transferpette S single and multichannel pipettes optimized for handling sensitive clinical samples. The pipettes are designed for ergonomic, one-handed volume adjustment, are completely user serviceable and fully autoclavable, and are CE-IVD compliant.

D-Dimer test kit, 10/16

October 2016—LGC Maine Standards announced its Validate D-Dimer calibration verification/linearity test kit has received 510(k) clearance for use on Instrumentation Laboratory’s ACL Top hemostasis test systems.

Cancer immunodiagnostic test, 10/16

October 2016—Boston-based Oncolab’s AMAS test detects circulating antibodies to a specific antigen (protein) produced by most types of cancer. The AMAS test can be used as a diagnostic aid in cancer occurrence and recurrence. More than 60,000 tests have been performed, and both its sensitivity and specificity are over 90 percent.

Cloud-based connectivity platform, 10/16

October 2016—Fio Corp. exhibited the Fionet platform, a cloud-based connectivity and reporting platform that enables real-time oversight, fragile network connectivity, and actionable insights for medical device manufacturers and health care providers.

Antigens, special protein reagents, 10/16

October 2016—Binding Site’s Immunological Group announced the addition of two rubella antigens and a cytomegalovirus antigen along with the availability of special protein reagents to in vitro diagnostic manufacturers.

The rubella antigens are derived and sourced from infected cells, via culture, which are then treated by UV irradiation to inactivate the pathogenic components. The ultra-purified and ultra-sensitive variant is ideal for the detection of IgM antibodies. The antigens are designed to benefit the needs of biopharmaceutical, clinical, and life science researchers, as well as manufacturers of IVD test kits, and exhibit exceptional purity levels as a result of cross-flow, ultra-filtration and centrifugation techniques.